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ABSTRACT 
 
Background: Patients with cancer face difficult decisions regarding treatment and the 
possibility of trading quality of life (QoL) for length of life (LoL). Little information is available 
regarding patients’ preferences and attitudes towards their cancer treatment and the 
personal costs they are prepared to exchange to extend their life. The aim of this review is 
to determine the complex trade-offs and underpinning factors that make patients with 
cancer choose quality over quantity of life.  
Methods: A systematic review of the literature was conducted using MeSH terms: cancer, 
longevity or length of life, quality of life, decision-making, trade off and health utility. 
Articles retrieved were published between 1942 to October 2018.  
Results: Out of 4393 articles, 30 were included in this review. Older age, which may be 
linked to declining physical status, was associated with a preference for QoL over LoL. 
Younger patients were more likely to undergo aggressive treatment to increase survival 
years. Preference for QoL and LoL was not influenced by gender, education, religion, having 
children, marital status or type of cancer. Patients with better health valued LoL and 
inversely those with poorer physical status preferred QoL.  
Conclusion: Baseline QoL and future expectations of life seem to be key determinants of 
preference for QoL versus LoL in cancer patients. In-depth studies are required to 
understand these trade-offs and the compromises patients are willing to make regarding 
QoL or LoL, especially in older patients with naturally limited life expectancy. 
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INTRODUCTION 
 
A diagnosis of cancer can be devastating and deciding on the appropriate treatment can be 
complicated and daunting. Patients are asked to consider factors that include mortality from 
the disease and the potential for acute and chronic morbidity from the treatment. 
Appropriate decision-making requires satisfactory patient understanding of these treatment 
choices, which includes the potential benefits and harms (1). The primary focus of cancer 
treatment has always been to increase overall and disease free survival, however, quality of 
life (QoL) has been increasingly recognised  as an important end-point (2).  
Although there is an instinctive understanding of the term “quality of life”, there are 
multiple definitions, which gives testimony to the fact that it is a complex concept with 
many diverse facets and components. The standard dimensions used in QoL questionnaires 
measure the presence or absence of specific symptoms or overall general health.  They do 
not measure patients’ beliefs or attitudes towards treatment and intervention outcomes 
(3).  Decision-making in a cancer setting can be a difficult process due to its multifaceted 
nature. The patients’ outlook and beliefs are paramount but this is heavily influenced by 
their own experiences and those of friends and family (5). In addition, current QoL and 
physical status can affect subsequent decisions. 
Most cancer trials primarily focus on the standard oncology end-points relating to survival 
but it is possible to derive composite measures which assess the impact of QoL on the final 
outcome of different therapies.  These are called quality adjusted survival metrics or health 
utility metrics and a wide range of them have been developed over the past 30 years. Utility 
measures allow patients a chance to value a different perspective on treatment and 
outcomes. Two methods of utility measurement which may be used to calculate quality 
adjusted life years (QALY) or quality adjusted survival are standard gamble and time trade-
off (TTO) (4).  In standard gamble, patients are asked to choose between staying in a state of 
ill health for a specified time period or choosing a treatment which may either cause their 
death or restore perfect health.  In the case of TTO, the individual expresses a preference 
between two choices,  usually between LoL or a better health status (5). These methods 
have been increasingly adapted in cost-utility analyses of pharmaceuticals and various 
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healthcare interventions. In reality scenarios are often more complex with disease and 
treatment effects impacting variably on QoL over a prolonged time course.  There may be a 
significant drop in QoL after an intervention but an overall better long term QoL and 
increased life expectancy. Quality of life measurement should not just focus on a single time 
point when assessing an intervention. 
In cancer treatment, patients are often required to make trade-offs between QoL and 
length of life (LoL) (6). Tumour-specific therapy can potentially prolong life; however, this 
may reduce QoL significantly. Some patients are willing to endure toxicities associated with 
treatment in order to increase their LoL, whilst others value QoL more and are reluctant to 
spend their remaining years in a compromised state (7). This involves weighing the risks and 
benefits of treatment and managing the patients’ concerns and expectations. There may be 
personal reasons associated with their health, the effect on their family and friends and the 
consequences of the treatment itself.  A trade-off for potential gain in life expectancy may 
involve short-term debility from treatment (post-surgical pain, chemotherapy induced 
nausea and alopecia etc.) or permanent side effects (stoma, disfigurement, physical 
dependency etc). Moreover, the compromise is not always related to health, but instead 
may be about financial burdens and increased dependency on friends and family. 
To understand cancer treatment choices concerning trade-off, various questionnaires and 
methodologies have been devised to understand patient preferences and priorities towards 
cancer treatment. Quality-Adjusted Time Without Symptoms or Toxicity (Q-Twist) allows the 
combination of both quality and quantity of survival time (8, 9). The principle hypothesis of 
this method is that patients without disease symptoms or treatment toxicity have a better 
health-related quality of life (HrQoL) than those who have disease specific symptoms and 
toxicity. Q-TWiST was initially used to assess adjuvant therapy for breast cancer and has 
now been adapted in other cancers (10-12). The Quality/Quantity Questionnaire designed 
by Stiggelbout and colleagues was created to assess patients’ preferences  towards either 
QoL or LoL when deciding about cancer treatments (7). Other methods include discrete 
choice experiments and various bespoke questionnaires tailored to a specific study (13-15). 
The aim of this review was to determine the factors influencing patient preferences for 
either quality of life or length of life and how these impacts on cancer treatment choices.  
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METHODOLOGY 
 
SEARCH STRATEGY AND SELECTION CRITERIA 
A systematic literature search was performed according to PRISMA guidelines using five 
databases between 1942 and October 2018. The databases included MEDLINE, SCOPUS, 
Cumulative Index to Nursing and Allied Health Literature (CINAHL), PsychINFO and Web of 
Science. A pilot search on MEDLINE, was performed to identify the relevant keywords 
contained in the title, abstract and subject descriptors. Five broad categories of concepts 
were searched: “quality of life”, “cancer”, “length of life”, “health utilities” and “decision 
making”. The search terms included (cancer* OR neoplasm* OR oncolog* or tumo?r*) AND 
(quality of life OR QoL) AND (Longevity OR Length of Life) AND (decision making OR patient 
participation OR patient preference OR patient participation OR treatment choice) AND 
(health state utilit* OR standard gambl* OR trade off). See Appendix A for the search 
strategy as used in Ovid Medline. The literature search was carried out by two authors (AS 
and CM). 
A study was only included if there was reference made to preference for QoL or LoL with or 
without determinants that may influence treatment choice. These factors could be either 
demographic influences, health status or personal factors. Study designs could be 
qualitative, quantitative or of mixed methods. Studies included were limited to adults with 
cancer and published in English. A PRISMA format was used to filter through articles. 
Editorials, reviews, and expert opinions were excluded. Hypothetical studies with healthy 
volunteers were also excluded as it was felt that these studies were unrealistic in their 
assessment of whether LoL or QoL would be favoured in a cancer setting.  Health status 
utilities were included in the search  to include any trade off papers  suitable for review. 
Time trade off studies may indicate treatment preferences, however not necessarily in the 
context of a preference for QoL versus LoL. Only those focusing on QoL versus LoL 
preferences were included. 
Study selection was by a  two-step process by 2 independent reviewers  (AS and CM), at  
titles and abstract stage with arbitration for articles with uncertainty.  In the second stage, 
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full-text articles were independently reviewed. (Figure 1)   Reference lists of all selected 
articles were reviewed to identify any additional relevant articles, identifying 5 further 
articles. When an article referred to additional publications for more details concerning 
study methods and design, those publications were also acquired. 
DATA ABSTRACTION 
Data extraction was performed by two independent reviewers (AS and CM). The 
information collected included study design, aim of study, location of study, sample size and 
response rate, age of the sample, type of cancer, any research tools used in the form of 
questionnaires and the findings of the study relating to QoL versus LoL preferences.  
 
QUALITY ASSESSMENT 
The Mixed Methods Appraisal Tool (MMAT) was used to quality assess the articles that were 
included in the study. The 2011 MMAT tool encompasses five types of mixed methods study 
components or primary studies: qualitative, quantitative randomized controlled trials, 
quantitative non-randomised, quantitative descriptive and mixed methods, each with its 
own set of methodological quality criteria. For each item the response categories were ‘yes’, 
‘no’, or ‘can’t tell’ followed by comments (16). Higher quality is denoted by the number of 
stars (*) in the tables.  Quality assessment was independently scored by two reviewers (AS 
and CM). No study was excluded based on quality assessment, as all were of acceptable 
quality.    
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RESULTS 
 
The literature search revealed 4388 articles. A total of 843 abstracts were excluded due to 
duplication and 3494 articles were declined as they were either reviews, expert 
opinions/editorials or not suitable for the topic under review. A total of 56 articles were 
reviewed fully and only 30 deemed suitable for inclusion. The 26 rejected papers were not 
suitable as they were either reviews or not relevant (Figure 1.)  Included studies are 
summarised in Tables 1 (quantitative), 2 (mixed methods) and  3 (purely qualitative).  
 
1st Author &Year 
published 
Country Aim Sample 
size 
[response 
rate %] 
Mean/median 
age in years 
[Range] 
Type of Cancer 
& Stage 
Questionnaires Results 
regarding 
QoL/LoL 
Quality of 
studies using 
MMAT 
Figure 1: PRISMA Flow chart of study selection 
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Kiebert (17) 
1994 
Netherlands 1. Investigate the 
importance of 
different factors on 
the trade-off  
2. Explore 
relationship 
between these 
importance ratings 
and personal 
characteristics 
212 NR 
18-75 
Testicular 
Breast 
Colorectal 
Lung 
Oesophagus 
Lymphoma 
Skin 
Prostate 
Self-designed 
questionnaire 
A priori chance 
of survival and 
baseline QoL 
considered 
important 
factors in choice 
of LoL or QoL 
** 
Stiggelbout (7) 
1996 
Netherlands Assess QoL versus 
LoL  
211 
NR 
NR 
<30-<71 
 
Breast 
Testicular 
Colorectal 
lung  
 
- QQ 
Questionnaire 
- Medical 
outcome short 
form general 
health survey 
(MOS SF-20) 
- Rotterdam 
symptom 
checklist (RSCL) 
- Younger 
patients 
preferred LoL 
- Those with 
poorer physical 
function 
preferred LoL 
than QoL 
- No difference 
in patients with 
cancer with good 
prognosis i.e. 
breast/ testicular 
versus recurrent 
colorectal/lung 
 
*** 
Helgason (18) 
1996 
Sweden Identify and 
measure the 
important disease-
specific distress for 
patients with 
prostate cancer 
319 
73 
NR 
50-80 
Prostate cancer Radiumhemmets 
Scale of Sexual 
Function 
63% of patients 
stated they 
would trade off 
the possibility of 
longer life over 
intact sexual 
function. 
**** 
Perez (3) 
1997 
New 
Zealand 
Assess how patients 
perceive their 
illness and make 
decisions about 
treatment.  
124 
62 
66 
18-91 
Metastatic 
cancer of any 
type 
Spitzer Quality 
of life Index and 
Uniscale 
- 37% were 
prepared to 
trade time for 
better QoL, 39% 
too well to 
consider any 
trade off, 24% 
did not want to 
trade time. 
- Patients willing 
to trade time 
had lower score 
in 4/5 domains  
*** 
Weeks (19) 
1998 
USA Do terminally ill 
patients understand 
their prognosis and 
treatment 
preference 
associated with 
comfort over life 
extension 
917 
55 
62 
NR 
- Stage III/IV 
lung cancer 
- metastatic 
colon cancer 
 
-Activities of 
daily living 
- Interview 
- Patient who 
thought their life 
expectancy was 
>6 months 
wanted life 
prolonging 
treatment  
** 
Silvestri (20) 
1998 
USA Assess treatment 
preferences by 
those who 
completed 
chemotherapy for 
non-small cell lung 
cancer and 
minimum survival 
benefit 
81 
100 
<60 - >70 Stage III and IV 
non-small cell 
lung cancer 
Scenario based 6% would have 
chemotherapy 
for even 1 week 
of extra survival, 
11% would not 
have 
chemotherapy 
even if there was 
potentially 24 
months of 
increased 
survival. 
*** 
List (21) 
2000 
USA Determine patients’ 
pretreatment 
choice regarding 
treatment effects 
and survival 
131 
96 
59 
29 – 87 
Head and Neck 
Stage II to IV 
- FACT H+N 
- Performance 
status scale for 
head and neck 
(PSS-HN) 
- Karnofsky 
75% ranked 
being cured of 
cancer as being 
most important, 
56% felt living as 
long as possible 
*** 
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Performance 
Scale 
- Bespoke 12 
item 
prioritization 
scale 
 
as an important 
priority. Those 
with better QoL 
wanted to be 
cured of cancer. 
Perez (22) 
2001 
New 
Zealand 
Measure the 
application of time 
trade-off utility 
measure 
64 
84 
58.7 
30-80 
Advanced 
breast cancer 
Spitzer Quality 
of life Index and 
Uniscale 
63% wanted to 
trade time, 32% 
felt they were 
too well to trade 
time. 
**** 
Donovan  (23) 
2002 
USA Assess women’s 
preferences for 
treatment in the 
case of recurrent 
ovarian cancer and 
identify factors 
associated with 
treatment 
preference 
81 
NR 
60.0 
NR 
Recurrent 
Ovarian Cancer 
- Profile of Mood 
States – Short 
Form 
- The Systems of 
Belief Inventory 
– 15R 
Satisfaction with 
Life Scale 
- Functional 
Assessment of 
Chronic Illness 
therapy – 
Spiritual Well-
Being Scale 
(FACIT-Sp) 
- FACT-G 
- FACT-O 
_ Decision Board 
Exercise 
- Women with 
ovarian cancer 
preferred 
salvage therapy 
to palliative 
treatment, in 
hope to increase 
LoL. QoL was a 
secondary 
consideration. 
- Iinitial 
treatment 
preference was 
not related to 
age, marital 
status, number 
of children, or 
employment 
status.  
 
*** 
Koedoot (24) 
2003 
Netherlands To what extent 
does information 
from friends, family 
and doctors affect 
treatment choice 
140 
68 
NR 
26-82 
Various types of 
metastatic 
cancer 
- Karnofsky 
Index 
- Rotterdam 
Symptom 
Checklist 
- Cancer Locus of 
Control Scale 
- Michigan 
assessment of 
decision style 
- QQ 
Questionnaire 
- 81% proposed 
that doctor 
suggested 
chemotherapy 
- Younger 
patients had a 
stronger 
preference for 
chemotherapy 
- Patients 
striving for QoL 
did not want 
chemotherapy 
**** 
Meropol (25) 
2003 
USA Understand the 
difference in 
perception and 
decision-making 
regarding 
participation in 
phase 1 cancer 
treatment trial in 
patients and 
doctors 
328 
55 
>18 years 
NR 
Advanced 
Cancer – not 
specified (31 
different types) 
-control 
preference scale 
- decisional 
conflict scale 
- SF-12 
- EuroQoL 
Health State 
Thermometer 
- Self-designed 
questionnaire 
- 5% of subjects 
responded LoL 
was more 
important 
 
*** 
List (26) 
2003 
USA Examine and 
compare the 
treatment priorities 
of newly diagnosed 
advanced stage 
head and neck 
cancer with a 
control group. 
247 
NR 
58 
25 – 87 
Head and neck 
II – IV 
FACT-HN 
PSS-HN 
12 item priority 
scale 
 
- Married 
prioritised LoL 
- Younger 
patients valued 
LoL more 
important than 
older patients. 
*** 
Derks (27) 
2005 
Netherlands Assess how age, 
sociodemographic 
data, comorbidity, 
social support 
depressive 
symptoms and QoL 
influence treatment 
choice. 
266 
NR 
NR 
45->80 
Head and neck 
Stage II-IV 
- EORTC-QLQ-
C30 
- EORTC-QLQ-
H&N35 
- Centre for 
Epidemiological 
studies 
Depressive 
Scale(CES-D) 
- Social Support 
List-Interactions 
(RSS12-I) 
- 
Quality/Quantity 
- 89% in 45-60 
age group 
received 
standard 
treatment 
compared to 
62% in >70 age 
old.  
- Elderly patients 
receiving non-
standard 
treatment 
reported QoL 
compared to 
*** 
   
10 
 
(QQ) 
Questionnaire  
those receiving 
standard 
treatment. 
 
Jansen (28) 
2006 
Netherlands Determine 
quantitatively 
patients’ 
perceptions of 
choice regarding 
treatment with 
adjuvant 
chemotherapy  
719 
62 
NR 
32-89 
Breast Cancer Self-designed 
questionnaire 
>80% patients 
underwent 
chemotherapy 
as LoL was 
considered 
important 
**** 
Meropol (13) 
2008 
USA Understand how 
patient preference 
(QoL/LoL) impact 
decision making 
748 
68 
>18 years 
NR 
Advanced 
cancer – not 
specified 
- Short-Form (SF-
12) 
- Revised Impact 
of Events Scale 
(RIES) 
- quality of life 
and length of life 
preference 
- 65% of patients 
felt QoL was 
more important 
than LoL, 
however, LoL 
matters, 19% 
thought vice 
versa; 15% 
thought QoL is 
all that matters 
and 1% thought 
LoL was all that 
mattered 
- Overall 55% felt 
both were 
equally 
important 
 
*** 
Wong (29) 
2013 
USA Assess patient 
characteristics that 
influence trade-offs 
584 
68 
61 
27-90 
Breast, 
prostate, GI, 
lung, 
head/neck, skin, 
haematological, 
other 
Discrete choice 
questionnaire 
Patients with 
higher income 
favored LoL. 
**** 
Laryionava (6) 
2014 
Germany Validate QQQ in the 
German Population 
309 
77 
52 
16-88 
- breast 
- lung 
- kidney 
- prostate 
- colon 
- rectum 
- pancreatic 
- bladder 
- others 
- QQ 
Questionnaire 
- Functional 
Assessment of 
Cancer Therapy 
–General (FACT-
G) 
- Cancer 
Communication 
Assessment Tool 
for patients 
(CCAT-P) 
- Questionnaire 
on Stress in 
Cancer Patients 
(QSC-R10) 
- Positive and 
Negative Quality 
in Marriage 
Scale (PANQIMS) 
- No difference 
in QoL and LoL in 
age, gender, 
patients with 
children and 
education 
- Unemployed 
patients 
preferred QoL to 
LoL 
- Family 
involvement in 
decision making 
correlated to LoL 
*** 
Marta (14) 
2014 
 
Brazil Assess the choices 
and priorities of 
patients with 
cancer, health care 
professionals and 
lay person 
regarding quantity 
and QoL 
250 
85.6 
 
56 
NR 
Gastrointestinal, 
breast, 
heamatological, 
lung, other 
Self-designed 
questionnaire  
21% of the 
patients agreed 
they would opt 
for treatment 
that prolongs 
survival, 
regardless of 
QoL. 15% would 
opt for 
treatment that 
would optimize 
QoL 
*** 
Krammer (30) 
2014 
Germany Examine attitudes 
towards melanoma 
therapy options and 
QoL versus LoL 
30 
NR 
57.5 
25-87 
Melanoma Bespoke 
Questionnaire 
- 44% of the 
patients were 
prepared to 
accept side 
effects for longer 
survival. 1/3 of 
the patients 
would rather live 
1 month longer 
than have a 
higher QoL at 
the end of their 
life. 
**** 
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- Older patients 
less likely to 
undergo 
treatment. 
Malhotra (31) 
2016 
Singapore Compare the 
attitudes of QoL 
and LoL between 
community 
dwelling older 
adults (CDOA) and 
advanced cancer 
patients 
1387 
NR 
62 
NR 
Stage IV cancer 
(all) 
QQ 
Questionnaire 
Overall QoL 
valued more 
than LoL. Cancer 
patients valued 
LoL above than 
QoL compared 
to the CDOA 
*** 
Danson (32) 
2016 
UK Assess HRQoL and 
smoking status at 
diagnosis and 
preference for 
treatments which 
promote QoL over 
LoL depending on 
smoking status 
304 
47.4 
65.6 
51 – 80 
Advanced Lung 
cancer 
- EORTC-QLQ-
C30 
- EORTC-QLQ-
LC13 
- QQ 
questionnaire 
- Significant 
preference for 
QoL over LoL 
irrespective of 
smoking status 
 
**** 
Pisu (33) 
2017 
USA Examine concerns 
of ovarian cancer 
patients and 
whether it varies in 
different age ranges 
170 
66 
61.8 
24-90 
 
Ovarian  
Stage I-IV 
Self-designed 
Questionnaire 
Patients felt 
maintaining QoL 
and living as long 
as possible both 
very important 
regardless of 
age. 
**** 
Table 1: Details of quantitative studies included in this review, associated with the trade-offs related to LoL and QoL  (NR – not  reported) 
 
 
         
1st Author &Year 
published 
Country Aim Sample 
size and 
[response 
rate %] 
Mean/median 
age in years 
[Range] 
Type of Cancer & 
Stage 
Questionnaires Results regarding 
Qol/LoL 
Quality of 
studies using 
MMAT 
Sekeres (34) 
2004 
USA Explore factors 
influencing the 
choice of 
induction 
chemotherapy or 
supportive care 
43 
98 
71  
60 – 85 
 
Acute myeloid 
leukemia  
Advanced 
myelodysplastic 
syndrome 
FACT-G 
FACT-An 
(Anaemia) 
SF-12 
Interview 
97% agreed QoL 
was more 
important than 
LoL 
*** 
Voogt (35) 
2004 
Netherlands Assess patients’ 
attitudes towards 
medical 
treatment  
200 
66 
63.5 
NR 
 
- Breast 
- Colorectal 
- Ovarian 
- Prostate 
(All Advanced 
cancer) 
 
- QQ 
Questionnaire 
- Positive and 
Negative affect 
scale 
- EORTC-QLQ-
C30 
- Interview 
- Younger patients 
preferred LoL 
- patients without 
partner preferred 
QoL 
- No difference in 
sex, children, 
education, 
religion, type of 
cancer. 
- Short history of 
cancer preferred 
LoL, patients 
preferred QoL 
were closer to 
death 
- attitudes did not 
change at 6 and 
12 months 
** 
Jenkins (36) 
2013 
UK Examine the 
experience and 
preferences of 
patients with 
advanced ovarian 
cancer regarding 
225 
52 
63.5 
31 – 83 
Ovarian Cancer 
I – IV 
- EORTC QLQ 
C30 
- EORTC QLQ 
INFO25 
-Interview 
 
33% proritised 
QoL as important, 
9% prioritized LoL 
and 57% felt both 
were important. 
*** 
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care and 
treatment 
Collins (37) 
2013 
USA Identify common 
themes from 
patient responses 
and identify 
factors associated 
with whether 
they would 
undergo palliative 
intervention in 
advanced cancer 
to relieve 
symptoms 
98 
NR 
59 
23-86 
NR but patients 
were admitted 
with bowel 
obstruction/ 
perforation, 
gastrointestinal 
bleed, abdominal 
pain, obstructive 
jaundice, 
malnutrition, 
infection. 
- FACT-G 
- Interview 
- 20 patients 
would undergo 
palliative 
intervention to 
treat cancer or live 
longer. 
-  47% for 
symptom control/ 
better QoL 
- Physicians’ 
recommendation 
was a strong 
influence 
*** 
DiBonaventura 
(15) 
2014 
USA Understand how 
patients’ trade off 
medication side 
effects with 
effectiveness 
and/or improved 
QoL 
181 
7 
52.2 
NR 
Metastatic 
Breast cancer 
- FACT-B 
- FACT-G 
- Interview 
- Treatment 
effectiveness 
(overall survival) 
most important to 
choosing 
chemotherapy for 
metastatic breast 
cancer 
 
*** 
Table 2: Details of mixed method studies included in this review, associated with the trade-offs related to LoL and QoL  (NR – not  reported) 
 
          
        
1st Author &Year 
published 
Country Aim Sample 
size and 
[response 
rate %] 
Mean/median 
age in years 
[Range] 
Type of Cancer 
& Stage 
Questionnaires Results 
regarding 
Qol/LoL 
Qualitiy of 
studies using 
MMAT 
Gerber (38) 
2012 
USA To gain insight into 
patients’ 
perceptions of 
maintenance 
chemotherapy 
13 
27 
62  
39 – 69 
Lung cancer 
 
Focus group 
Interview 
Trade off issues 
highlighted 
“…with the 
maintenance are 
we going to be 
able to go on 
with life, so not 
just be totally ill 
all the time or do 
we want to take 
a chance and be 
with our family 
and loved ones 
and have some 
quality of life 
left?” 
*** 
Brom (39) 
2014 
Netherlands Obtain insight into 
patients’ 
preferences and 
the reasons for 
patients’ ideas of 
preferred role in 
treatment decision-
making whether to 
start a life 
prolonging 
treatment 
28 
[NR] 
NR 
18->81 
- Glioblastoma 
- Metastatic 
Colorectal 
Cancer 
Interview - Some patients 
felt they would 
stop treatment if 
it affected QoL. 
- Several 
patients felt 
“doing nothing” 
wasn’t an option 
and unwilling to 
accept transition 
from LoL to QoL 
to death. 
*** 
Berry (40) 
2015 
USA Explore and 
understand the 
aspects and 
process of 
treatment decision 
making perceived 
by patients with 
bladder cancer 
60 
42 
66 
33-86 
Bladder cancer 
Stage 0a-IV 
Interview - 38% felt 
survival was the 
main feature of 
treatment 
decision, 
balancing 
toxicities and 
LoL.   
*** 
Table 3: Details of purely qualitative  studies included in this review, associated with the trade-offs related to LoL and QoL  (NR – not  reported) 
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The majority of studies identified in this review were quantitative. Generic questionnaires 
(EORTC-QLQ-C30 and FACT-G) and disease specific questionnaires (EORTC-QLQ-H&N) were 
used to assess QoL. The studies were mainly conducted to understand the decision-making 
process in the advanced cancer setting.  The studies had wide focus which included 
understanding the role of the doctor and the attitude the patient has towards their 
treatment, amongst other themes. Understanding QoL and LoL trade-offs as part of the 
decision-making process, usually formed a limited part of many of these studies. 
 
QUALITY OF LIFE VERSUS LENGTH OF LIFE 
Meropol and colleagues (2008) suggested that QoL and LoL are both equally important, 
however, the majority of  patients with advanced cancer in this study prioritized  QoL over 
LoL (41). This was also reflected by the study of Jenkins and associates (36). Silvestri and 
associates noted although there were some patients who would endure treatment and 
associated toxicities just to live a single day longer, there were also patients who would 
decline all treatments.  These latter patients would rather maintain their QoL and having to 
withstand the side effects of treatment would not be a worthwhile trade-off (20). The 
authors postulated that  patients may opt for enhanced QoL only if the chance of survival 
was less than 50% relative to baseline survival (without treatment) (42).  
Many patients in the study by Brom and colleagues felt that they ought to have some sort of 
intervention for their cancer and found it difficult to accept the concept of LoL and QoL. 
Although some patients opted for treatment initially, they expressed the view that if it was 
affecting their QoL, they would cease treatment (39). Marta and colleagues noted that the 
majority of  patients in their study wanted to undergo a treatment that would prolong life 
but not compromise their QoL (43). In a qualitative study by Gerber and colleagues, patients 
stated that they were keen to maintain their activities and not be a burden on family, and 
therefore not undergo chemotherapy if those factors were compromised, indicating the 
importance of QoL (38). 
 
SURVIVAL AND BASELINE QUALITY OF LIFE 
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Survival seemed to be a key feature in the decision-making process and patients were found 
to opt for treatment if they felt that their prognosis was likely to improve (15, 19, 28, 40). 
Their current health status also affected their choice. Perez and associates found that those 
who wanted to trade time, scored lower in many of the domains of the baseline HRQoL 
questionnaires (3). Patients in better health were found to rate LoL more highly, whereas 
those who were in poorer health strived to maintain their QoL (7, 22, 32, 44). Kiebert and 
associates noted that issues patients felt were important were baseline QoL and the 
probability of survival (17). 
 
DEMOGRAPHIC FACTORS 
Kiebert and associates assessed factors affecting decision-making for cancer treatment and 
noted that important factors were age, marital status, children, inability to work due to side 
effects, disease related life expectancy and baseline QoL. No significant associations were 
found between the various determinants, however, patients did rate having children and 
marital status as somewhat important in decision making (17).  
Other studies have shown different results, with gender, children, education, religion and 
cancer type not influencing treatment choices (3, 6, 23, 35). Those with strong family links 
preferred survival. Unemployed patients prioritised QoL (6). Wong and colleagues 
concluded that those who were able to pay for their treatment chose to have treatment to 
prolong their life (45). These latter findings are only relevant in self paying health care 
systems. 
Many of the studies carried out have not been age specific, therefore, it has been difficult to 
make inferences about the influence of age on LoL/QoL preferences.  The studies in this 
review show a mixed picture. Older patients have a preference for QoL, which is not 
surprising considering natural limitations to life expectancy and the often reduced QoL 
associated with advanced age (34). Younger cancer patients were more likely to tolerate 
aggressive treatments to increase survival years (30, 35, 46). A study by Pisu and colleagues 
involving 170 ovarian cancer patients, showed that maintaining QoL and living as long as 
possible were both important. In women <65 years, 96.9% felt longevity was important and 
95.9% felt that preserving QoL was important, compared to 87.5% and 90.3% respectively, 
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in the >65-year age group  (33).  Stiggelbout and associates noted that when age was 
adjusted for in their statistical calculations, those in relationships and with children 
preferred longevity (7). Derks and colleagues found that older patients were less likely to 
receive standard treatment, an effect that was more evident in those above the age of 80 
years. Reasons behind this included lack of social support and being widowed. Patients who 
did not receive standard treatment also prioritized QoL more strongly (27).   
 
SYMPTOM TRADE-OFF 
When looking at symptom tradeoffs against longevity, patients were prepared to tolerate 
certain treatment side effects to live longer. Patients were willing to prioritise survival over 
intact sexual function in prostate cancer for instance (18, 44). When patients with advanced 
cancer reached the end of their lives and had to endure pain and discomfort, 47% of 
patients chose to have palliative surgery to maintain or enhance their current health status 
and independence (37).    
 
CANCER SPECIFIC TRADE-OFF 
Patients suffering from cancers with a good prognosis such as breast and testicular cancers, 
compared to recurrent colorectal or lung cancer had similar thoughts regarding QoL and LoL 
(7). Despite the type of cancer, patients felt that QoL and LoL were equally important when 
considering treatment (41). In the study by Pisu and colleagues involving ovarian cancer, 
more than 90% stated that QoL and LoL were equally important (33). Another study by 
Jenkins and associates, involving participants with ovarian cancer showed that 57% felt LoL 
and QoL were equally important, 9% prioritised LoL and 33% favoured QoL (36). However, 
Donovan and colleagues demonstrated that women who had recurrent ovarian cancer, 
would opt for LoL, and choose to receive aggressive treatment, QoL was a secondary issue 
(23).   Patients with a shorter history of cancer preferred LoL, however, those with poorer 
prognosis and closer to their predicted time of death valued QoL more (35). In contrast, 
Meropol and colleagues, found that there was no association between time since diagnosis 
and QoL/ LoL preference (41).  
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DISCUSSION 
 
This study presents the first comprehensive review of studies looking at trade-offs between 
QoL and LoL in a cancer setting. The aim of this review was to highlight whether patients 
prioritise QoL or Lol and the determining factors that influence the decision-making process 
for cancer treatment.  In fact, the findings indicate that many of the studies don’t directly 
test determinants. The QQ questionnaire has been designed specifically to quantify the 
patient’s choice of QoL or LoL and also, to what extent patients would be inclined towards 
either. The questionnaire does not capture the psychological reasoning behind the 
preference however. It is also perhaps more suited for patients with advanced cancers 
where the cancer will inevitably cause death regardless of whether it was treated or not (7).  
For some patients, where curative treatments may be available, albeit with a high cost (for 
example, mutilating operations leading to disfigurement i.e. head and neck resections, 
mastectomy, amputations etc.) or where death due to old age or other, non-cancer 
comorbidities is imminent, this trade-off may also be relevant and the QQ tool is not 
designed to explore these scenarios. 
This review highlights the importance of carrying out baseline QoL assessments prior to 
treatment and evaluating the impact of life expectancy.  The importance of performing age 
specific studies is also noted as priorities between younger and older patients are different. 
The preferences for QoL or LoL by younger patients, may be influenced by their desire to 
spend time with their partner or children. Older patients are more likely to suffer from 
multiple co-morbidities and be frailer and discussions may need to include whether a 
treatment will be tolerated less well due to these limitations, or result in an increased risk of 
harm. Considerations should include patient intolerance to certain chemotherapy agents or 
surgery, as well as an understanding that they may never reach their pre-operative baseline 
physical fitness again after treatment. This ‘step down’ in function tends to be more 
prominent in the older age group (47, 48), an effect which is widely recognized across many 
medical interventions in older patients. They may feel that time spent receiving treatment 
may not be worth the extension of life for a relatively short period.  Older individuals have a 
good overall understanding that they have lived their lives and are more accepting of the 
inevitability of death and of their physical limitations. Studies suggest that  a good  QoL in 
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older people is often based around: independence, a strong social circle, and an ability to 
retain their ‘inner-selves’ (49). These values may be compromised by having treatment. 
Other studies have shown that the most consistent factor influencing treatment decision 
making in older patients is a recommendation from doctors (50). In breast cancer, under-
treatment is well-documented in older patients (51). This has led to avoidable disease-
specific deaths (52). Exploring the patients’ views regarding treatment at an early stage 
would help reduce the impact of age-related clinician bias which is well recognised (53). 
 
STUDY LIMITATION 
This study is the first to use a rigorous and systematic approach to review studies based on 
patient preferences regarding QoL or LoL in a cancer treatment setting. Despite a 
comprehensive database search strategy, it is possible that some relevant articles may have 
been missed and despite the various methodologies, all papers included were of an 
acceptable design and standard for inclusion. However, the main findings of the review are 
likely to be robust to missing studies. Based on our interpretation and weighting of the 
evidence we are confident in the conclusions that has been drawn from findings across 
several studies rather than be based on isolated studies. None of the studies in this review 
has looked at the impact of pre-existing, non-cancer related limitations to life expectancy as 
part of this trade-off, such as is seen in the oldest age groups and the impact of acceptance 
of impending age-related mortality. With the aging of Western populations, this is an 
important gap in the literature.   
The studies included in this review are exploratory cohort studies carried out in a 
retrospective manner, whereby patients have already made their decision regarding 
treatment. There may be a source of  bias influencing their responses, as many issues may 
not have been considered prior to treatment or the decision-making process.  
Many of these studies have mainly focused on advanced cancers of all types. For patients 
who are facing mortality imminently, the decision to prioritise QoL and LoL is pertinent. In 
the case of slow growing cancers such as prostate and breast cancers, where conservative 
management is widely accepted, the choice between QoL and LoL can be more complicated. 
Patients often  die from other causes rather than the cancer itself (54). As the majority of 
   
18 
 
the articles identified in this search did not involve early stage cancer, it is difficult to know 
what patients envisage from their treatment, and what trade-offs they were willing to make 
as well as how these factors may change with the course of the natural disease process. This 
is where patients’ age and co-morbidities may play a larger role in whether the patient opts 
for QoL or LoL.  
 
CLINICAL IMPLICATIONS 
This review has several important clinical and research implications. With treatment and 
care now becoming more patient centered, it has become more pertinent to understand the 
impact of the cancer diagnosis on the patient and the motivations behind their treatment 
choices. The impact of treatment of certain cancers may be extreme and may involve a 
great deal of compromise and acceptance of change in circumstances. Factoring the likely 
impact of treatments on QoL relative to that at baseline should be discussed with every 
patient. This would ensure that patients have a full understanding of what their treatment 
entails and that they are aware of the consequences of treatment and non-treatment. 
Further in-depth studies are required to understand the emotional and physical 
considerations and personal priorities the patients may have during the decision-making 
process. This may go a long way in elucidating what aspects of their life they are willing to 
trade to maintain their QoL or increase LoL.  Older age specific issues and cancer specific 
decision-making processes also need exploring. 
 
CONCLUSION 
Decision-making in cancer treatment is difficult as there are multiple components to 
consider aside from the purely medical aspects. Likewise, the compromises the patient is 
willing to make can vary greatly depending on many factors including patient age, personal 
family dynamics, social structures, and, patients’ likely survival and baseline QoL. This may 
subsequently impact on whether the patient is more incline 11d towards longevity or QoL.  
Although there are studies trying to understand the factors influencing the final decision, 
there is limited information on preferences between QoL and LoL and the trade-off the 
patient is willing to make. Clinicians have influence over the final decision, and therefore, it 
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is vital for the patient to have a full understanding of their treatment and the impact it may 
have on their life.   
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